Navigation Links
Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
Date:5/22/2008

ROCKVILLE, Md., May 22 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has created a new proprietary process to develop a vaccine candidate against Severe Acute Respiratory Syndrome (SARS). The company also received renewed research funding from the National Institutes of Health (NIH) to continue preclinical development of SARS vaccine candidates using Novavax's virus-like particle (VLP) technology.

"Until now, it has been difficult to produce VLP vaccine candidates against SARS and other complex infectious disease targets because many of these biological structures do not assemble efficiently," said Dr. Gale Smith, Vice President, Vaccine Development. "Our new proprietary process uses select components of SARS and other structural proteins that combine with cell membranes to form distinctive SARS coronavirus nanoparticles, which are nearly identical to the human SARS virus but lack the genetic material needed to replicate and cause disease."

"This new approach to create VLPs will allow us to continue our work to develop a SARS vaccine candidate and expand the potential applications of our vaccine technology to a broad range of infectious diseases around the world," said Rahul Singhvi, President and Chief Executive Officer of Novavax, Inc.

Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a coronavirus and was first reported in Asia in February 2003. According to the World Health Organization (WHO), subsequent to the 2003 breakout, over 8,000 people were infected, with 774 reported deaths. While there is currently no known reported SARS transmission globally, WHO and other such agencies continue to monitor the SARS situation on a global basis as health officials remain concerned that SARS or similar disease could reemerge.

The SARS VLP program is conducted under an NIH grant. Novavax does not have the commercial rights to this product candidate.

About Novavax '/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
2. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
3. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
4. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
5. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
6. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
7. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
8. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
9. BARC Announces Long-Term Cooperation In South African Biobanking for HIV Vaccine Trials
10. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
11. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Calif. , Aug. 1, 2014  Isis Pharmaceuticals, ... initiation of a pivotal Phase 3 study evaluating ISIS-SMN ... the most common genetic cause of infant mortality. Isis ... within the next few weeks, at which time Isis ... development partner, Biogen Idec. The Phase 3 study, ENDEAR, ...
(Date:8/1/2014)... Aug. 1, 2014 Inovio Pharmaceuticals, Inc. (NYSE ... conference call to report its second quarter 2014 financial ... ET. CEO Dr. J. Joseph Kim and ... earnings, provide a corporate update, and participate in a ... development plans for VGX-3100, Inovio,s immune therapy targeting pre-cancers ...
(Date:8/1/2014)... Aug. 1, 2014 Arena Pharmaceuticals, Inc. ... corporate update and reported financial results for the ... "We have continued to see encouraging advancements ... 43% quarter-over-quarter increase in estimated total prescriptions and ... mark," said Jack Lief, Arena,s President and Chief ...
Breaking Medicine Technology:Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11
(Date:8/1/2014)... use among young people has spiked, with 29.3 percent ... at least once and 17 percent admitting to regular use ... ‘Yes to Life,’ volunteers from the Church of Scientology of ... information about drugs, to help reverse this alarming trend. , ... Say ‘Yes’ to Life,” volunteers have distributed 40,000 copies of ...
(Date:8/1/2014)... appetite and whole-body metabolism. A protein known as PPARγ ... and body weight, but the identity of the neurons ... new study in the Journal of Clinical Investigation ... neuron known as pro-opiomelanocortin (POMC) neurons is critical in ... and colleagues at Yale University School of Medicine found ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- The U.S. ... approved a new drug, Jardiance, to help fight type ... alone or added to existing treatment regimens to control ... Dr. Curtis Rosebraugh, director of the Office of Drug ... and Research, said in an agency statement. The ...
(Date:8/1/2014)... Summer is here, and with it comes the season of ... can be a pain for dogs. Animal Emergency & Referral ... get rid of ticks and prevent them completely. , Female ... which is why they are so active during this season. ... and carry a number of diseases, including lyme disease, babesiosis ...
(Date:8/1/2014)... of a cancer diagnosis may improve health outcomes for ... by a researcher at the University of Houston (UH). ... intervention is the writing instruction. Otherwise, writing is just ... journal can be therapeutic, but oftentimes we don,t get ... not," said Qian Lu, assistant professor and director of ...
Breaking Medicine News(10 mins):Health News:Addressing a Serious Issue Affecting German Teens 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:Tis the Season for Tick Prevention 2Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3
... Core Administration Software with ... PLANO, Texas, May 15 Perot Systems (NYSE:,PER) ... Core,Administration Software. Xcelys 5.0 software is a continuance of ... health plan market., Xcelys, formerly called PERADIGM software, ...
... of shingles cases, expert says , , THURSDAY, May ... older should be vaccinated against shingles, a condition that ... Disease Control and Prevention recommended on Thursday. , This ... 2006, after the ZOSTAVAX vaccine was approved by the ...
... pump inhibitors (PPIs) to control gastroesophageal reflux disease ... take them continue to experience breakthrough, which is ... regurgitation and heartburn. These breakthrough symptoms lead more ... (OTC) remedies, according to a survey recently conducted ...
... YORK, May 15 Pharmaceutical research and,development (R&D) is ... years and,a billion dollars of investment to turn a ... journey from discovery to market, is filled,with challenges. For ... makes it to the market. "From Molecule to Medicine," ...
... that,the U.S. Court of Appeals for the Federal Circuit ... District Court for the Central District of,California in the ... As a result of the Court of Appeals, ruling, ... Sanofi-aventis is considering all its legal options., While ...
... Diabetes,Wholesale (ADW), a discount provider of diabetic supplies, is ... network. ADW hopes to,expand its online reach and strengthen ... affiliate partners a percentage of every sale they refer.,Commissions ... our affiliate,program as a great way to cultivate an ...
Cached Medicine News:Health News:Perot Systems Announces the Launch of Xcelys(TM) 5.0 Software 2Health News:CDC Recommends Shingles Vaccine for Those Over 60 2Health News:CDC Recommends Shingles Vaccine for Those Over 60 3Health News:Nearly 40 percent of GERD patients taking PPIs experience recurring symptoms 2Health News:Nearly 40 percent of GERD patients taking PPIs experience recurring symptoms 3Health News:District Court Decision Affirmed in U.S. Lovenox(R) (enoxaparin sodium) Patent Infringement Case 2Health News:American Diabetes Wholesale Launches Affiliate Program 2
... The True/Fix Ankle Fusion Nail ... that provides the maximum strength, support ... in the ankle joint, yet preserves ... reducing the potential of tibial fracture ...
... BP-Tel enhance the llifestly of hypertensive ... "White Coat Effect" normally associated with ... and clinics. A user-friendly, one-step ... routine blood pressure monitoring from the ...
... patient cable and 4 metal chest ... unit. 3-step procedure enabling a patient ... 12 lead ECG through a simple ... 2.5 seconds per lead and 10 ...
... comprehensive information system designed specifically to ... and streamline their diagnostic, management, and ... software solution. Thousands of laboratory professionals ... proven PowerPaths unique "case-centric model to ...
Medicine Products: